This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study, all subjects need to use TQH2929 injection/placebo. The aim was to demonstrate the efficacy and safety of TQH2929 injection in patients with acute exacerbations of generalized pustular psoriasis, with a total of 36 subjects.
Age ≥ 18 or ≤75 years old at screening, regardless of gender;
Meet the diagnostic criteria defined by the 2017 European Society for Clinical Nutrition and Metabolism (ESPEN) Research Workshop (ERASPEN) consensus and be diagnosed as （generalized pustular psoriasis(GPP);
Compliant with GPP acute onset;
Able to read and understand, and willing to sign the informed consent form;
Pustules are limited to psoriasis vulgaris on psoriasis plaques;
Concomitant skin disease or medical disease that may interfere with the investigator's evaluation of the subject's treatment response;
Serum virological abnormalities during the screening period;
Chest radiology examination shows that the subject has active tuberculosis or a history of contact with open tuberculosis subjects in the past 6 months or a positive Interferon-Gamma Release Assays(IGRA) test;